CorMedix Inc. (CRMD)

6.13
0.14 2.23
AMEX : Health Technology
Prev Close 6.27
Open 6.28
Day Low/High 6.10 / 6.28
52 Wk Low/High 4.20 / 13.70
Volume 119.37K
Avg Volume 274.00K
Exchange AMEX
Shares Outstanding 25.65M
Market Cap 156.21M
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
CRMD INVESTOR ALERT: Investigation Of CorMedix, Inc., Announced By Glancy Prongay & Murray LLP

CRMD INVESTOR ALERT: Investigation Of CorMedix, Inc., Announced By Glancy Prongay & Murray LLP

Glancy Prongay & Murray LLP announces that it is investigating potential claims on behalf of investors of CorMedix, Inc.

Cormedix (CRMD): Today's Weak On High Volume Stock

Cormedix (CRMD): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Cormedix (CRMD) as a weak on high relative volume candidate

EQUITY ALERT: The Rosen Law Firm Announces Investigation Of Securities Claims Against CorMedix, Inc. - CRMD

EQUITY ALERT: The Rosen Law Firm Announces Investigation Of Securities Claims Against CorMedix, Inc. - CRMD

The Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of investors of CorMedix, Inc.

Biotech Stock Mailbag: Unstoppable Heron, Aerie Disclosure Fail, Gene Therapy, Hate Mail!

Biotech Stock Mailbag: Unstoppable Heron, Aerie Disclosure Fail, Gene Therapy, Hate Mail!

Biotech columnist Adam Feuerstein answers readers' questions about health care.

CorMedix (CRMD) Stock Gains After Receiving Positive FDA Feedback for Neutrolin

CorMedix (CRMD) Stock Gains After Receiving Positive FDA Feedback for Neutrolin

CorMedix (CRMD) shares are rising after the company said that the FDA gave positive feedback for its catheter lock solution for oncology patients.

Cormedix (CRMD): Today's Weak On High Volume Stock

Cormedix (CRMD): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Cormedix (CRMD) as a weak on high relative volume candidate

Oversold Conditions For CorMedix (CRMD)

Oversold Conditions For CorMedix (CRMD)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Trade-Ideas: Cormedix (CRMD) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: Cormedix (CRMD) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified Cormedix (CRMD) as a weak on high relative volume candidate

Strong On High Relative Volume: Cormedix (CRMD)

Strong On High Relative Volume: Cormedix (CRMD)

Trade-Ideas LLC identified Cormedix (CRMD) as a strong on high relative volume candidate

January 2017 Options Now Available For CorMedix (CRMD)

January 2017 Options Now Available For CorMedix (CRMD)

Investors in CorMedix Inc saw new options begin trading today, for the January 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 610 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Trade-Ideas: Cormedix (CRMD) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: Cormedix (CRMD) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified Cormedix (CRMD) as a weak on high relative volume candidate

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BAK, BWC, ENDP, FNBC, GBLI, HAYN, MEET, NAT, TGI Downgrades: AAME, CUDA, DDD, DNR, DRC, ELGX, FMC, GTN, MGCD, NMRX, RKUS, SHLO, TPC Initiations: ALLY, CHMI, CRMD, ENBL, EVDY, FPI, LQ, QURE, TWOU Read on to get TheStreet Quant Ratings' detailed report:

4 Stocks Under $10 Making Big Moves

4 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

The Top-Performing Biotech Stock During a Sizzling First Quarter

The Top-Performing Biotech Stock During a Sizzling First Quarter

That was one crazy first quarter for the biotech sector. Here's where biotech stocks stand on April Fool's Day.

Interesting CRMD Call Options For May 15th

Interesting CRMD Call Options For May 15th

Investors in CorMedix Inc saw new options become available this week, for the May 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRMD options chain for the new May 15th contracts and identified the following call contract of particular interest.

A Steady but Sloppy Day

Awaiting Yellen, but some churn wouldn't hurt.

3 Stocks Raising The Drugs Industry Higher

3 Stocks Raising The Drugs Industry Higher

TheStreet highlights 3 stocks that pushed the Drugs industry

4 Biotech Stocks Under $10 to Trade for Breakouts

4 Biotech Stocks Under $10 to Trade for Breakouts

These under-$10 biotech stocks are within range of triggering breakout trades.

3 Biotech Stocks Under $10 to Trade

3 Biotech Stocks Under $10 to Trade

Keep your eye on these under-$10 biotech stocks.

It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013

It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013

Biotech and drug stocks are up almost 9% to start 2014, trouncing the broader market averages.

CorMedix Receives CE Mark For Neutrolin® Catheter Lock Solution

CorMedix Receives CE Mark For Neutrolin® Catheter Lock Solution

CorMedix Inc. (NYSE MKT: CRMD) today announced that it has received CE Mark approval for Neutrolin®, a catheter lock solution, for patients with central venous catheters on hemodialysis secondary to advanced...

CorMedix Reports Year End 2012 Financial Results

CorMedix Reports Year End 2012 Financial Results

CorMedix Inc. (“CorMedix”) (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announces its financial...

CorMedix Granted Extension Of NYSE MKT Listing

CorMedix Granted Extension Of NYSE MKT Listing

CorMedix Inc. (“CorMedix”) (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announces the receipt ...

CorMedix Signs Sales And Marketing Agreement With MKM Co-Pharma, Bolsters Commercial Management Team To Ready Neutrolin® Catheter Lock Solution For European Market

CorMedix Signs Sales And Marketing Agreement With MKM Co-Pharma, Bolsters Commercial Management Team To Ready Neutrolin® Catheter Lock Solution For European Market

CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announced today that it has signed ...

CorMedix: Final Closing Of 2012 Financing

CorMedix: Final Closing Of 2012 Financing

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, held the second and ...

CorMedix Successfully Completes And Passes ISO 13485 Certification Audit

CorMedix Successfully Completes And Passes ISO 13485 Certification Audit

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announced today...

CorMedix: Initial Close On Financing And Extension Granted To Regain Compliance With NYSE Amex Listing Standards

CorMedix: Initial Close On Financing And Extension Granted To Regain Compliance With NYSE Amex Listing Standards

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, held the initial ...

CorMedix: Granted Extension Of NYSE Amex Listing

CorMedix: Granted Extension Of NYSE Amex Listing

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, announces the receipt...

CorMedix Provides An Update On CE Marking Process For Neutrolin® In The EU

CorMedix Provides An Update On CE Marking Process For Neutrolin® In The EU

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, announces the receipt...

CorMedix Receives NYSE Amex Notice Of Delisting For Non-Compliance

CorMedix Receives NYSE Amex Notice Of Delisting For Non-Compliance

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), is a development stage pharmaceutical and medical device company that seeks to in-license, develop and commercialize therapeutic products for the treatment of ...

TheStreet Quant Rating: D+ (Sell)